对ASCCP 2012年宫颈癌筛查和癌前病变管理指南的解读(二)  

The Interpretation of 2012 ASCCP Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors(Ⅱ)

作　　者：王荣敏[1] 彭晶晶[1] 尤志学[2] 

机构地区：[1]南京医科大学第一临床医学院,210029 [2]南京医科大学第一附属医院妇科

出　　处：《国际妇产科学杂志》2015年第2期238-240,共3页Journal of International Obstetrics and Gynecology

摘　　要：宫颈癌病因明确,发展过程中存在较长的可逆性的癌前病变期,是可通过医学干预降低发病率和死亡率的恶性肿瘤。随着宫颈癌筛查的开展和推广,宫颈上皮内瘤变(CIN)患者逐年增多且有年轻化趋势。而对癌前病变的管理及干预是阻止浸润癌发生的重要环节。结合美国阴道镜检查和宫颈病理学会(ASCCP)2013年颁布的《2012年宫颈癌筛查和癌前病变全球共识指南》针对宫颈癌前病变的处理方式进行解读。新版指南更清晰提出各级别CIN的分层处理及CIN治疗后的联合随访的价值,对指导临床规范化处理具有重要的价值。Cervical cancer with definite pathogenic factors exits longer and reversible premalignant lesions which can be intervened by medical methods to decrease the morbidity and mortality. With the development of cervical cancer screening, more and more women especially young women were found with cervical intraepithelial neoplasia （CIN）. The management and intervention of precancerous lesions is an important link to prevent invasive carcinoma. Combined with American Society for Colposcopy and Cervical Pathology （ASCCP） in 2013 promulgated ＂2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors＂, we interpretated the management of cervical precancerous lesions. The uptated guidelines of great importance to direct the clinical practice prescribed the management of CIN and highlighted the follow-up value of cotest.

关 键 词：宫颈肿瘤 普查 宫颈上皮内瘤样病变 细胞学技术 乳头状瘤病毒科 

分 类 号：R737.33[医药卫生—肿瘤]